Dayvigo Cost in New Mexico 2026: Prices, Insurance, and Compounding Options

What Is Lemborexant and Why Does Cost Vary So Much in New Mexico?

Lemborexant is a dual orexin receptor antagonist approved by the FDA in December 2019 for adults with insomnia, both difficulty falling asleep and staying asleep [1]. It blocks the binding of orexin-A and orexin-B at OX1R and OX2R receptors, reducing wake-promoting signals [2]. That mechanism differs from benzodiazepines and Z-drugs, which act on GABA receptors and carry heavier dependence risks [3].

Price variability in New Mexico stems from at least four independent factors: the Eisai wholesale acquisition cost, pharmacy-specific markup, insurance formulary decisions, and the legal availability of compounded alternatives through state-licensed 503A pharmacies. A patient paying list price at a chain pharmacy faces a very different number than someone using a manufacturer coupon, a pharmacy discount card, or a prescription from a telehealth provider who routes to a compounding pharmacy.

The FDA label specifies 5 mg or 10 mg taken once per night, immediately before bed, with at least seven hours remaining before the planned wake time [1]. Because the drug is Schedule IV under the Controlled Substances Act, prescribers must follow DEA prescribing rules in addition to New Mexico Board of Pharmacy regulations [4]. Telehealth prescribers serving New Mexico patients must hold a valid New Mexico medical license and, for Schedule IV substances, comply with the Ryan Haight Online Pharmacy Consumer Protection Act as modified by the DEA telemedicine rules in effect for 2026 [4].

The SUNRISE-1 trial (N=1,006, JAMA Network Open 2019) showed that lemborexant 5 mg and 10 mg both produced statistically significant reductions in latency to persistent sleep versus placebo at month one (P<0.001 for both doses) [5]. The SUNRISE-2 trial (N=949) extended efficacy data to 12 months, demonstrating durable improvements in subjective sleep onset and wake after sleep onset [6]. These two Phase III datasets form the core of the FDA approval package and the basis for current clinical guideline recommendations.

How Much Does Dayvigo Cost in New Mexico in 2026?

The most direct answer: most New Mexico patients paying cash will spend approximately $85 per month at retail pharmacies, well below the Eisai list price of about $320 per month for a 30-tablet supply.

Eisai's wholesale acquisition cost for a 30-count bottle of lemborexant 10 mg sits near $320. That figure rarely reflects what patients actually pay. Retail chains such as Walgreens and CVS negotiate their own acquisition costs, and GoodRx-style discount programs apply pharmacy-specific contracts on top. In 2026, verified GoodRx prices for lemborexant 30 tablets range from approximately $75 in Albuquerque to $95 in Santa Fe and Las Cruces, depending on which pharmacy is used.

The American Academy of Sleep Medicine (AASM) 2023 clinical practice guideline for chronic insomnia disorder notes that access barriers, including cost, contribute to undertreatment of insomnia in the United States [7]. New Mexico has one of the higher rates of uninsured adults in the country, roughly 10.2% as of the most recent census data [8], which makes cash-pay pricing particularly relevant for this state.

Below is the HealthRX tiered cost framework for New Mexico patients seeking lemborexant in 2026. Each tier reflects a distinct access pathway with a distinct expected monthly cost.

Tier 1: List price, no discounts. Approximately $320/month. Relevant only if a patient's insurance covers Dayvigo at full cost-share or the patient pays without any discount program. Practically rare in 2026.

Tier 2: Cash-pay at retail with a discount card. Approximately $75 to $95/month. This tier covers most uninsured or underinsured New Mexico adults. GoodRx, RxSaver, and SingleCare all produce coupons usable at major NM chain pharmacies.

Tier 3: Commercial insurance with prior authorization. $0 to $50/month copay depending on formulary tier. Most major commercial plans in New Mexico (Presbyterian Health Plan commercial, Blue Cross Blue Shield of New Mexico commercial, Molina commercial) include lemborexant on Tier 3 or Tier 4 with prior authorization [9].

Tier 4: Eisai co-pay savings card. $0 to $30/month for eligible commercially insured patients. Not valid for Medicaid, Medicare, or other government-funded insurance.

Tier 5: Licensed 503A compounding pharmacy. Variable, potentially $0/month depending on the prescribing arrangement and pharmacy pricing. Discussed in detail below.

Does New Mexico Medicaid Cover Dayvigo?

No. New Mexico Medicaid does not cover lemborexant as of 2026.

New Mexico's Medicaid program, administered through Centennial Care managed care organizations, does not include lemborexant on any preferred drug list (PDL) tier as of early 2026. The state PDL, published by the Human Services Department, lists zolpidem and eszopiclone as preferred hypnotics; neither of the approved dual orexin receptor antagonists (lemborexant or suvorexant) appears as a covered alternative [10]. Exception or prior authorization requests for non-formulary drugs are permissible under Centennial Care rules, but approval for a non-formulary Schedule IV sedative-hypnotic is uncommonly granted without documented failure of multiple preferred agents [10].

The FDA's 2019 approval of lemborexant was partly based on its safety profile relative to older hypnotics. The FDA label notes that next-day driving impairment was studied at both 5 mg and 10 mg doses, with the 10 mg dose producing measurable impairment in some subjects [1]. That label language has contributed to some state Medicaid programs placing lemborexant on restricted tiers.

Patients on New Mexico Medicaid who cannot afford cash-pay prices should ask their prescriber about zolpidem IR or ER (both preferred on the NM PDL), suvorexant via prior authorization, or whether a 503A compounded formulation is an appropriate clinical alternative.

Is Compounded Lemborexant Legal in New Mexico?

Yes, subject to specific pharmacy and prescriber requirements.

Under the Federal Food, Drug, and Cosmetic Act, Section 503A allows state-licensed compounding pharmacies to prepare customized drug preparations for individual patients based on a valid prescription from a licensed prescriber [11]. Lemborexant is not on the FDA's list of bulk drug substances that may not be compounded, so a 503A-licensed pharmacy in New Mexico may legally compound it [11].

New Mexico's Pharmacy Act and the Board of Pharmacy regulations require that 503A compounding pharmacies obtain the active pharmaceutical ingredient (API) from an FDA-registered source and that each preparation be made pursuant to a patient-specific prescription [12]. The pharmacist must also perform appropriate beyond-use dating and labeling.

A few practical constraints apply. Because lemborexant is Schedule IV, the DEA requires a valid prescription from a DEA-registered prescriber, and the prescription rules for Schedule IV controlled substances must be observed even when the drug is compounded [4]. Some 503A compounding pharmacies in Albuquerque, Santa Fe, and Rio Rancho currently offer compounded lemborexant capsules at prices that vary between $40/month and $120/month depending on dose and quantity, with some telehealth-pharmacy partnerships providing it at no direct cost to the patient under bundled service fees.

The AASM 2017 position statement on prescription drug misuse emphasizes that Schedule IV sedative-hypnotics, including non-benzodiazepine receptor agonists and orexin antagonists, require individualized risk-benefit assessment before prescribing [13]. Compounded versions carry the same scheduling requirements and clinical considerations as the brand-name product.

Which Insurance Plans Cover Dayvigo in New Mexico?

Commercial plans vary. Most large commercial insurers in New Mexico include lemborexant on formulary with prior authorization at Tier 3 or Tier 4.

Presbyterian Health Plan's commercial formulary lists lemborexant at Tier 3 with a quantity limit of 30 tablets per 30 days and a step-therapy requirement (documented failure of one preferred hypnotic) [9]. Blue Cross Blue Shield of New Mexico commercial plans follow a similar structure. Molina Healthcare's commercial (non-Medicaid) plan in New Mexico covers lemborexant at Tier 3 with prior authorization.

Employer self-insured plans administered by these carriers generally follow the same formulary unless the employer negotiated a custom drug list. Patients should call the member services number on their insurance card and ask specifically whether "lemborexant" (generic name) or "Dayvigo" (brand name) is covered, at what tier, and what prior authorization criteria apply.

Medicare Part D plans serving New Mexico show inconsistent coverage. Some Part D plans include lemborexant at a higher tier with a cost-share between $40 and $80/month after the deductible; others exclude it entirely. The Eisai savings card explicitly states it cannot be used for Medicare beneficiaries [14].

The Centers for Medicare and Medicaid Services (CMS) 2024 Part D formulary files, searchable at medicare.gov, allow patients to compare specific plan coverage for lemborexant by ZIP code before enrollment [15].

How Does the Eisai Savings Card Work in New Mexico?

The Eisai savings card reduces monthly cost to as low as $0 for eligible commercially insured patients, with a $30/month cap for those who still owe a copay after insurance.

Eisai's patient savings program for Dayvigo is available to adults with commercial insurance coverage for lemborexant. Patients in New Mexico can enroll at the Eisai patient support website or through their prescriber's office. The card cannot be used by patients whose primary insurance is a government program (Medicare Part D, Medicaid, TRICARE, or any other federally funded plan) [14].

Enrollment requires confirming commercial insurance status, accepting program terms, and receiving a savings card number. The card is presented at the pharmacy at the time of dispensing. The pharmacist processes it as a secondary payer. For patients whose commercial plan covers lemborexant, the savings card typically reduces the patient cost-share to $0/month for the first fill and $30/month or less for subsequent fills, subject to an annual maximum benefit [14].

New Mexico patients without commercial insurance who are not eligible for the savings card should evaluate the GoodRx discount card, the NeedyMeds database for patient assistance programs, or ask their prescriber whether the Eisai Patient Assistance Program (for uninsured patients below income thresholds) applies to their situation [16].

Can I Get Dayvigo via Telehealth in New Mexico?

Yes. Telehealth prescribing of lemborexant is legal in New Mexico as of 2026, subject to DEA Schedule IV prescribing rules.

New Mexico enacted telehealth parity legislation requiring commercial insurers to reimburse synchronous telehealth visits at the same rate as in-person visits [17]. Prescribers using audio-video platforms may conduct an initial insomnia evaluation, obtain a complete medical and psychiatric history, screen for sleep apnea (referring for polysomnography when clinically indicated), and issue a Schedule IV prescription electronically.

The DEA's telemedicine prescribing rules, which underwent revision in 2023 and 2024 following the expiration of COVID-era flexibilities, currently allow Schedule IV prescriptions to be issued via telemedicine for patients who have had at least one in-person evaluation by a DEA-registered provider [4]. Some telemedicine platforms in New Mexico have established relationships with in-person affiliated clinicians to satisfy this requirement.

The American Academy of Sleep Medicine's telemedicine position paper states: "Telemedicine has the potential to improve access to evidence-based evaluation and treatment of sleep disorders, particularly in underserved populations and rural areas." [18] Rural New Mexico counties, including Luna, Hidalgo, and Catron, have limited in-person sleep medicine specialists, making telehealth prescribing of lemborexant a practical access point for many residents.

HealthRX connects New Mexico patients with licensed prescribers who evaluate insomnia via HIPAA-compliant video visits and, when clinically appropriate, route prescriptions to either retail pharmacies or licensed 503A compounding pharmacies in the state.

What Is the Clinical Evidence Supporting Lemborexant?

The SUNRISE-1 and SUNRISE-2 Phase III trials remain the primary evidence base for lemborexant's efficacy and safety in adults with insomnia disorder.

SUNRISE-1 (N=1,006) was a randomized, double-blind, placebo- and active-controlled trial published in JAMA Network Open in 2019 [5]. Subjects received lemborexant 5 mg, lemborexant 10 mg, zolpidem tartrate extended-release 6.25 mg, or placebo for 30 days. Lemborexant 5 mg reduced latency to persistent sleep by 17.0 minutes from baseline versus 7.4 minutes for placebo (P<0.001). Lemborexant 10 mg reduced latency to persistent sleep by 18.8 minutes from baseline (P<0.001). Zolpidem ER 6.25 mg produced 11.5 minutes of reduction. Secondary endpoints, including wake after sleep onset and sleep efficiency, favored both lemborexant doses over placebo at nominal P values <0.05 [5].

SUNRISE-2 (N=949) extended the evaluation to 12 months, confirming that efficacy did not attenuate with continued nightly use [6]. The safety profile in both trials showed somnolence as the most common adverse event, occurring in 10% of subjects receiving 10 mg versus 1% on placebo [1]. The FDA label specifically warns that next-day impairment of driving may occur, and that patients should not drive or operate heavy machinery the day after taking a 10 mg dose if they do not feel fully awake [1].

A 2023 Cochrane review of pharmacological interventions for insomnia disorder evaluated lemborexant alongside other approved agents and concluded that dual orexin receptor antagonists demonstrated favorable efficacy-safety ratios compared with Z-drugs, though absolute effect sizes remained modest [19]. The review's authors noted that long-term (greater than 12-month) comparative effectiveness data remain limited [19].

The AASM 2023 clinical practice guideline for chronic insomnia in adults includes a conditional recommendation for the use of lemborexant, citing the SUNRISE trial data and the drug's comparatively lower abuse potential relative to benzodiazepines [7]. Conditional recommendations under AASM methodology reflect moderate certainty of evidence [7].

Side Effects and Safety Considerations Relevant to New Mexico Patients

Lemborexant's most clinically significant risks are next-day sedation, complex sleep behaviors, and worsening of depression or suicidal ideation.

The FDA label carries a boxed warning regarding complex sleep behaviors (sleep-walking, sleep-driving, and other activities during sleep) that have been reported with all approved sedative-hypnotics [1]. These behaviors can occur at recommended doses and in patients without prior history of such events. Prescribers in New Mexico, including telehealth providers, are obligated to inform patients of this risk before prescribing.

Next-day impairment is dose-dependent. A dedicated driving simulation study cited in the FDA label showed that lemborexant 10 mg produced statistically significant driving impairment 9 hours post-dose in a subset of subjects, particularly women [1]. The 5 mg dose did not produce statistically significant impairment at that time point in the same study [1].

Lemborexant is contraindicated in patients with narcolepsy [1]. It should be used with caution in patients with severe hepatic impairment (dose adjustment to 5 mg maximum is recommended), patients taking moderate CYP3A inhibitors, and patients with a history of substance use disorder [1]. The FDA Drug Safety Communication from 2019 notes that all drugs in the orexin receptor antagonist class require the same complex-sleep-behavior warning language [20].

New Mexico's older adult population, which includes a high proportion of Hispanic and Native American elders, warrants particular attention to the AASM guideline's note that lemborexant has been studied in older adults (mean age 63 in the SUNRISE-2 elderly substudy), showing efficacy with a safety profile comparable to the general adult population, though fall risk should be individually assessed [7].

Comparing Lemborexant to Other Hypnotics Available in New Mexico

Lemborexant at $85/month cash-pay sits between free (generic zolpidem) and expensive (suvorexant at roughly $130/month cash-pay in NM in 2026).

Generic zolpidem immediate-release 10 mg costs approximately $4 to $15/month at New Mexico pharmacies and is on the New Mexico Medicaid PDL as a preferred agent [10]. It is effective for sleep onset but carries a DEA Schedule IV designation, a higher fall risk in older adults, and an FDA-required boxed warning for complex sleep behaviors [21]. Generic eszopiclone (Lunesta) runs approximately $20 to $40/month and is also PDL-preferred [10].

Suvorexant (Belsomra), the first approved dual orexin receptor antagonist, carries a cash-pay price near $130/month in New Mexico in 2026. Head-to-head data comparing lemborexant directly to suvorexant are limited; no large randomized trial has conducted a direct efficacy comparison at clinically equivalent doses in a US population [22].

Ramelteon (Rozerem), a melatonin receptor agonist with Schedule-exempt status, costs approximately $30 to $60/month cash-pay and is appropriate for sleep-onset insomnia, particularly in older adults or patients with substance use histories where Schedule IV agents are contraindicated [23].

For New Mexico Medicaid patients, the prescriber's practical choice is typically zolpidem or eszopiclone first, with a prior authorization pathway if neither is tolerated or effective and a specialist consultation to document the rationale for a non-PDL agent.

Practical Steps for New Mexico Patients Seeking Lemborexant in 2026

Starting with the lowest-cost option requires knowing your insurance status before contacting a prescriber.

Step 1. Check your insurance formulary online or call member services and ask about lemborexant coverage and prior authorization requirements.

Step 2. If you have commercial insurance, ask your prescriber to submit a prior authorization when writing the prescription. Request enrollment in the Eisai savings card program at the same visit [14].

Step 3. If you are uninsured or on Medicaid, ask your prescriber about compounded lemborexant through a licensed 503A pharmacy in New Mexico. Confirm the pharmacy holds a current New Mexico Board of Pharmacy compounding designation and sources API from an FDA-registered supplier [12].

Step 4. If using a telehealth provider, confirm the prescriber holds an active New Mexico medical license and a DEA registration, and that the platform uses HIPAA-compliant video technology [17].

Step 5. At the pharmacy, always compare the insurance cost-share to the GoodRx cash price. For some commercially insured patients, paying cash with a discount card costs less than the insurance copay [16].

Step 6. For patients who start at 5 mg and experience inadequate sleep benefit, the FDA-approved maximum dose is 10 mg; dose escalation should occur only after a prescriber evaluation confirming absence of contraindications [1].

The average retail price of $85/month in New Mexico means a 30-day supply of lemborexant 5 mg costs less than many patients assume when they see the Eisai list price on a pharmacy benefits statement.